Related Experiment Video
Updated: May 16, 2025
08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
9.5K
Investigation of PDE5 effect on NOS in nasal polyp pathophysiology
Vahit Mutlu1, Zülküf Kaya2, Zekai Halıcı3
1Department of Otorhinolaryngology, Atatürk University Faculty of Medicine, Yakutiye, Erzurum, 25240, Turkey. drvahit@gmail.com.
Summary
This study found that phosphodiesterase type 5 (PDE5) levels were lower, while inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) levels were higher in nasal polyps. These findings suggest their involvement in nasal polyp pathophysiology.
Area of Science:
- Rhinology and Otolaryngology
- Inflammation and Immunology
- Molecular Biology and Biochemistry
Background:
- Nasal polyps are inflammatory masses linked to chronic mucosal inflammation.
- Nitric oxide (NO) plays a role in inflammation, and phosphodiesterase (PDE) enzymes regulate its production.
- Phosphodiesterase type 5 (PDE5) regulates cyclic guanosine 3'-5'-monophosphate (cGMP) signaling, influencing NO pathways implicated in nasal congestion.
Purpose of the Study:
- To investigate the role of PDE5, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) in the pathophysiology of nasal polyps.
- To examine the expression of these molecules in nasal polyp tissue with mucosal edema.
Main Methods:
- Nasal mucosal tissues were collected from 25 patients with nasal polyps and 25 controls.
- Levels of eNOS, iNOS, and PDE5 were quantified using Enzyme-Linked Immunosorbent Assay (ELISA).
Main Results:
- PDE5 levels were significantly decreased in the nasal polyp group compared to the control group.
- iNOS and eNOS levels were significantly increased in the nasal polyp group relative to controls.
- No significant demographic differences were noted between the groups, except for age.
Conclusions:
- The study suggests that altered levels of iNOS, eNOS, and PDE5 are implicated in the pathophysiology of nasal polyps.
- These findings highlight the potential involvement of nitric oxide signaling pathways in the development of nasal polyps.
More Related Videos
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
104
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
104
01:23Antihypertensive Drugs: Vasodilators
440
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
440
01:30Pulmonary Hypertension: Classification and Pathogenesis
123
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
123
01:16Antianginal Drugs: Nitrates and β-Blockers
459
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
459
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
124
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124